Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury. (MSC)
|Spinal Cord Injury||Other: Autologous Adipose Derived Mesenchymal Stem Cells||Phase 1|
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Safety of Autologous Adipose Derived Mesenchymal Stem Cells in Patients With Spinal Cord Injury|
- safety evaluation [ Time Frame: 12weeks ]Safety evaluate through physical examination, vital sign and laboratory test after "RNL-Astrostem" injected
|Study Start Date:||July 2009|
|Study Completion Date:||February 2010|
|Primary Completion Date:||November 2009 (Final data collection date for primary outcome measure)|
Other: Autologous Adipose Derived Mesenchymal Stem Cells
Adipose derived mesenchymal stem cells (AdMSCs) represent an attractive and ethical cell source for stem cell therapy.
With the recent demonstration of MSC homing properties, intravenous aplications of MSCs to cell-damaged diseases have increased.
In a human clinical trial, eight male patients who had suffered a spinal cord injury were intravenously administered autologous hAdMSCs (4×10e8 cells) one time.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01274975
|Principal Investigator:||SangHan Kim, MD||Anyang Sam Hospital|